The chemical of craving

Marano, Hara Estroff
July 1997
Self;Jul97, Vol. 19 Issue 7, p58
Provides information on neuropeptide Y, a brain chemical which acts as an appetite stimulator. Possibility that the chemical could be able to stem obesity in the United States; Outline of medical research relating to the drug being carried out by American drug companies; When and how the chemical was identified.


Related Articles

  • Orlistat for obesity?  // Consumer Reports on Health;Jul99, Vol. 11 Issue 7, p7 

    Provides information on orlistat, an obesity drug that suppresses appetite. Clinical trial results; Mechanism of action; Side effects; Need for diet and exercise to ensure that weight loss will last.

  • The weight is over.  // Men's Health;Jun98, Vol. 13 Issue 5, p38 

    Presents information on Meridia, an anti-obesity drug approved by the United States Food and Drug Administration. How Meridia reduces the hunger of a person; Advantage of Meridia from other anti-obesity drug.

  • Diet pills. Raeburn, Paul // Glamour;Aug96, Vol. 94 Issue 8, p42 

    Focuses on questions about the value of diet drugs. Food and Drug Administration's (FDA) approval of Redux or dexfenfluarmine; Risk of primary pulmonary hypertension; Importance of regular exercise; Redux's suppression of hunger pangs by acting on serotonin; Maintaining weight loss; Research...

  • Diet pills are coming back. Toufexis, Anastasia; Park, Alice // Time International (South Pacific Edition);5/20/96, Issue 21, p63 

    Reports on the approval of the first antiobesity drug, called dexfenfluramine, in 23 years by health officials in the United States. Brand name, drug will be sold under; Historic information on the diet pill; Effectiveness of the drug; Expectations to approve more diet drugs; Safety of the...

  • Drugs for obesity are last resort treatment. Bower, Hilary // BMJ: British Medical Journal (International Edition);06/07/97, Vol. 314 Issue 7095, p1643 

    States that appetite suppressant drugs should be prescribed as a last resort treatment for obese patients in Great Britain. Crackdown on inappropriate use of slimming drugs by the Royal College of Physicians of London; Benefits obese patients may get from desfenfluramine; Side effects of taking...

  • Efficacy and Tolerability of Orlistat in Obese Patients. Nuovo, Jim // American Family Physician;8/1/2000, Vol. 62 Issue 3, p649 

    Presents an abstract of the study `Orlistat in the long-term treatment of obesity in primary care settings,' by J. Hauptman, et al., from the February 2000 issue of `Archives of Family Medicine.'

  • Double-blind Evaluation of Mazindol in Refractory Obesity. Smith, R.G.; Innes, J.A.; Munro, J.F. // British Medical Journal;8/2/1975, Vol. 3 Issue 5978, p284 

    Evaluates the effect of mazindol on refractory obesity. Stimulation of the central nervous system; Decrease in body mass index; Role of anorectic agents in the modification of eating habits.

  • Phen/fen combination for weight control. R.M.D. // Cortlandt Forum;7/25/96, Vol. 9 Issue 7, p137 

    Provides information on the safety and proper administration of phentermine and fenfluramine used in combination for appetite suppression. Effectiveness in treating obesity; How the agents act as appetite depressants; Recommended use of the agents as part of a comprehensive weight control...

  • Information superhighway. Wilson, Clare // New Scientist;4/9/2011, Vol. 210 Issue 2807, p37 

    The article, part of a section on the use of electrical brain stimulation for cognitive enhancement, discusses the use of vagus nerve stimulation for control of obesity, noting a stimulator made by the company Cyberonics and comparative risks of the surgery versus stomach stapling.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics